You searched for side effects - Page 85 of 311 - Medivizor
Navigation Menu

Does neratinib plus capecitabine benefit patients with heavily treated HER2-positive metastatic breast cancer?

Does neratinib plus capecitabine benefit patients with heavily treated HER2-positive metastatic breast cancer?

Posted by on Aug 20, 2020 in Breast cancer | 0 comments

In a nutshell This trial compared the effectiveness of neratinib (Nerlynx) plus capecitabine (Xeloda) in treating metastatic breast cancer compared to lapatinib (Tykerb) plus capecitabine in patients who have received 2 or more treatment lines. The authors found that neratinib plus capecitabine (N+C) resulted...

Read More

Does thiazide use result in a decreased risk of heart failure in patients taking intensive blood pressure treatment?

Does thiazide use result in a decreased risk of heart failure in patients taking intensive blood pressure treatment?

Posted by on Aug 20, 2020 in Hypertension | 0 comments

In a nutshell This study examined whether thiazide use had a benefitted patients receiving intensive blood pressure (BP) treatment for high blood pressure (HBP) in terms of heart disease risk. The authors found that these patients had a decreased risk of having an adverse cardiovascular event.  Some background Hypertension...

Read More

The impact of checkpoint blockade therapy in making Hodgkin lymphoma sensitive to future treatment

The impact of checkpoint blockade therapy in making Hodgkin lymphoma sensitive to future treatment

Posted by on Aug 16, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated whether exposure to checkpoint blockade therapy (CBT) can make relapsed/refractory (R/R) Hodgkin lymphoma (HL) sensitive to further treatments. The main finding was that CBT may make patients with R/R-HL responsive to further treatments. Some background While a large percentage of patients with HL can ve cured with...

Read More

Evaluating antithymocyte globulin in preventing graft-versus-host-disease after matched sibling donor transplantation

Evaluating antithymocyte globulin in preventing graft-versus-host-disease after matched sibling donor transplantation

Posted by on Aug 16, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the role of antithymocyte globulin in preventing graft-versus-host disease after matched sibling donor transplantation.  This study concluded that this treatment can reduce the occurrence of graft-versus-host-disease in these patients.   Some background One...

Read More

Evaluating antithymocyte globulin in preventing graft-versus-host-disease after matched sibling donor transplantation

Evaluating antithymocyte globulin in preventing graft-versus-host-disease after matched sibling donor transplantation

Posted by on Aug 16, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the role of antithymocyte globulin in preventing graft-versus-host disease after matched sibling donor transplantation. This study concluded that this treatment can reduce the occurrence of graft-versus-host-disease in these patients.   Some background One treatment option for patients with blood...

Read More

Is tapering glucocorticoids safe in rheumatoid arthritis after achieving low disease activity?

Is tapering glucocorticoids safe in rheumatoid arthritis after achieving low disease activity?

Posted by on Aug 16, 2020 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated tapering glucocorticoids (GCs) in rheumatoid arthritis (RA) patients who have achieved low disease activity (LDA). They found that continuing GCs at a low dose was more effective at sustaining LDA.  Some background Rheumatoid arthritis (RA) is a chronic condition. Excess inflammation causes painful...

Read More

Evaluating patient-reported outcomes in the treatment of metastatic non-small-cell lung cancer with pembrolizumab plus pemetrexed–platinum

Evaluating patient-reported outcomes in the treatment of metastatic non-small-cell lung cancer with pembrolizumab plus pemetrexed–platinum

Posted by on Aug 15, 2020 in Lung cancer | 0 comments

In a nutshell The study evaluated treatment outcomes reported by patients with metastatic non-small-cell lung cancer (mNSCLC) who were treated by pembrolizumab (Keytruda) and pemetrexed (Alimta) and platinum chemotherapy. The authors found that adding pembrolizumab to pemetrexed-platinum chemotherapy improved health-related quality of life (HRQOL)...

Read More

Improving the tolerability of neratinib in patients with early-stage HER2-positive breast cancer.

Improving the tolerability of neratinib in patients with early-stage HER2-positive breast cancer.

Posted by on Aug 15, 2020 in Breast cancer | 0 comments

In a nutshell This trial evaluated strategies to improve diarrhea as a side effect of neratinib (Nerlynx) treatment in patients with HER2-positive breast cancer (BC). The authors showed that slowly increasing the doses of neratinib or taking anti-diarrhea medication can improve this side effect. Some background Neratinib (Nerlynx) is a targeted...

Read More

Looking for patients with untreated extensive-stage small cell lung cancer to trial a immunotherapy combination

Looking for patients with untreated extensive-stage small cell lung cancer to trial a immunotherapy combination

Posted by on Aug 15, 2020 in Lung cancer | 0 comments

In a nutshell This trial is examining the effectiveness of atezolizumab (Tecentriq) plus carboplatin (Paraplatin) and etoposide (Etopophos) with or without tiragolumab in patients with untreated extensive-stage small-cell lung cancer (ES-SCLC). The main outcomes that will be measured are progression-free survival (PFS) and overall survival...

Read More

Searching for patients with advanced breast cancer to trial an experimental drug combination

Searching for patients with advanced breast cancer to trial an experimental drug combination

Posted by on Aug 15, 2020 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the safety of experimental treatment zanidatamab (ZW25) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) in patients with advanced breast cancer (BC). The main outcomes evaluated will be the rate of side effects and survival without cancer worsening. This trial is...

Read More